Internationally Recognized Translational Scientist Appointed Senior Vice President at Roswell Park

Monday, July 27, 2009

BUFFALO, NY – James L. Mohler, MD, an internationally recognized prostate cancer translational scientist who has led the development of minimally invasive surgery for urologic cancers at Roswell Park Cancer Institute (RPCI), has been appointed Senior Vice President for Translational Research.

“Dr. Mohler has set a high standard for integrity, superb clinical care and evidenced-based approaches to therapy of urologic cancers and cutting-edge basic and translational research since he joined the Roswell Park faculty in 2003,” said Donald L. Trump, MD, FACP, President and CEO at Roswell Park. “The robust translational research program at Roswell Park will benefit from his expanded executive leadership.”

Dr. Mohler joined RPCI in 2003 as Chair of the Department of Urologic Oncology and as the leader of RPCI’s Prostate Program. He also serves as Professor of Urology at the University at Buffalo School of Medicine and Biomedical Sciences. His laboratory focuses upon the role of the androgen receptor and androgen metabolism in prostate cancer and his clinical practice focuses upon robotic prostatectomy.

“Researchers, who want their science to be directly applicable to the clinic, gravitate to places such as Roswell Park, a cancer institute that is committed to translational research,” said Dr. Mohler. “I am honored to take on the additional responsibilities of leading this group of well-regarded professionals as they pursue their individual scientific endeavors, which ultimately will offer new insights into the causes and treatment of cancer by bridging laboratory discoveries with clinical insights.”

Dr. Mohler earned his medical degree from the Medical College of Georgia, Augusta, and completed an internship in Internal Medicine at Duke University Medical Center, Durham, NC; residency training in Surgery and Urology at the University of Kentucky Medical Center, Lexington; and a research fellowship in Urologic Oncology at The Johns Hopkins University School of Medicine, Baltimore, MD. Dr. Mohler is a co-founder of AndroBioSys, Inc., which is pioneering new human tissue-based models for drug testing and developing new treatments for prostate disease.

Dr. Mohler is Chair of the National Comprehensive Cancer Network (NCCN) Prostate Cancer Guidelines Committee, past-President of the Society for Basic Urologic Research and Vice-Chair of the Urology Committee of the Cancer and Leukemia Group B (CALGB), and is a member of the American Medical Association, American Urological Association, American Association for the Advancement of Science, American Association for Cancer Research, American Urological Association and the American College of Surgeons.

The mission of Roswell Park Cancer Institute (RPCI) is to understand, prevent and cure cancer. RPCI, founded in 1898, was one of the first cancer centers in the country to be named a National Cancer Institute-designated comprehensive cancer center and remains the only facility with this designation in Upstate New York. The Institute is a member of the prestigious National Comprehensive Cancer Network, an alliance of the nation’s leading cancer centers; maintains affiliate sites; and is a partner in national and international collaborative programs. For more information, visit RPCI’s website at http://www.roswellpark.org, call 1-877-ASK-RPCI (1-877-275-7724) or email askrpci@roswellpark.org.

Media Contact: 

Annie Deck-Miller, Senior Media Relations Manager
716-845-8593; annie.deck-miller@roswellpark.org